Abstract: SA-PO0835
Assessing the Risk of Thromboembolic Events and the Role of Prophylactic Anticoagulation in Saudi Patients with Primary Nephrotic Syndrome
Session Information
- Glomerular Management: Real-World Lessons and Emerging Therapies
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Elfar, Ahmed F., King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Alnaeem, Khalid Ahmed, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Alkhdiri, Mohamad Hamad, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Alzeyedi, Rawan Saleh, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Alhawati, Fahad Saleem, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Almuammar, Saud, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Alqarni, Khaled Abdullah, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Alrajhi, Eman A, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
- Mohamed, Gamal, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia
Background
Studies have shown that risk of thromboembolism in nephrotic Syndrome varies from 7-40%. Membranous nephropathy has been shown to have the highest risk.
Methods
A retrospective cohort study using data from electronic medical records from January 2011 until December 2022.The study included patients with biopsy-proven minimal change disease (MCD), FSGS, membranous nephropathy, and IgA nephropathy with nephrotic syndrome.
Results
Among 169 patients with nephrotic syndrome, thromboembolism was observed in 9.47 % of cases. Membranous and IgA nephropathies showed the highest incidence at 12.8 % and 10%, respectively. The thromboembolism percentages across the groups was not statistically significant (p=0.772).The vast majority (94%) were not on any anticoagulant therapy, and they had thromboembolic events at a rate of 9.4%. One patient on warfarin had thromboembolic event, while no events were reported among users of Apixaban, Heparin, or Enoxaparin. The association between anticoagulant use and thromboembolic events was not statistically significant (p = 0.88).Among patients who had thromboembolic events, 62.5% had albumin <20 g/L.
Conclusion
Thromboembolic risk is about 9.4% among Saudi patients with nephrotic syndrome with membranous nephropathy representing the highest risk. Anticoagulation is effective in reducing the risk. We noted no significant difference in reducing thromboembolic risk among different classes of anticoagulants.
| Anticoagulant | No Thromboembolism | Thromboembolism | Total |
| None | 144 90.57 | 15 9.43 | 159 100.00 |
| Warfarin | 4 80.00 | 1 20.00 | 5 100.00 |
| Apixaban | 2 100.00 | 0 0.00 | 2 100.00 |
| Heparin | 2 100.00 | 0 0.00 | 2 100.00 |
| Enoxaparin | 1 100.00 | 0 0.00 | 1 100.00 |
| Total | 153 90.53 | 16 9.47 | 169 100.00 |
Pearson chi2 (4)= 1.1702 Pr- 0.883